Scarica l'app Stockscreener
53.78
0.94%
-0.51
Pre-mercato:
54.14
0.36
+0.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$54.29
Aprire:
$54.46
Volume 24 ore:
1.63M
Relative Volume:
0.73
Capitalizzazione di mercato:
$8.96B
Reddito:
$1.56B
Utile/perdita netta:
$152.72M
Rapporto P/E:
59.80
EPS:
0.8994
Flusso di cassa netto:
$221.80M
1 W Prestazione:
-1.47%
1M Prestazione:
+21.43%
6M Prestazione:
+81.32%
1 anno Prestazione:
+79.39%
Intervallo 1D:
$53.36
$54.90
Intervallo di 1 settimana:
$53.36
$55.67
Portata 52W:
$25.16
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
53.78 | 8.96B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
16.61 | 53.04B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.71 | 42.76B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.10 | 38.54B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.08 | 31.48B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
552.48 | 23.45B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-29 | Downgrade | BofA Securities | Neutral → Underperform |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Alkermes plc Files 8-K Termination Report: Company Overview, NASDAQ Listing, and Key Details (July 2026) - Minichart
Alkermes plc outlines its role in neuroscience therapies as a global biopharmaceutical company - AD HOC NEWS
Insider Sell: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes stock hits 52-week high at 55.28 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 55.28 USD - Investing.com
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) notice: David Gaffin lists proposed Common Stock sales in 2026 - Stock Titan
Price to earnings forward of Alkermes plc – NASDAQ:ALKS - TradingView
Granules India secures sole First-to-File status for generic drug - The Times of India
ALKSAlkermes plc Volatility & Greeks - Finviz
(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Bull Case For Alkermes (ALKS) Could Change Following Vibrance-12 Data And Russell 2000 Inclusion - simplywall.st
ALKS Maintains Rating by Mizuho -- Price Target Raised to $65 - GuruFocus
Mizuho raises Alkermes stock price target to $65 on narcolepsy drug potential - Investing.com
Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (ALKS) shows multiple 9,000-share insider sales, exercise and vesting - Stock Titan
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 AdditionWhat's Changed - Yahoo Finance
A Look at Alkermes PLC (ALKS) After 4.8% Decline -- GF Value $31 - GuruFocus
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
ALKS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
ALKS Downgraded by B of A Securities -- Rating Changed to Underp - GuruFocus
BofA downgrades Alkermes stock rating on valuation concerns By Investing.com - Investing.com Australia
BofA downgrades Alkermes stock rating on valuation concerns - Investing.com
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS - TradingView
Press Release: Alkermes to Report First Quarter Financial Results on May 5, 2026 - Moomoo
Price to sales forward of Alkermes plc – NASDAQ:ALKS - TradingView
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda - BioPharma Dive
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes Public Limited Company Actuals & Estimates (NASDAQ:ALKS) - TradingView
ALKS Forecast — Price Target — Prediction for 2027 - TradingView
Alkermes stock hits 52-week high at 51.77 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 51.77 USD - Investing.com
Liquidity Mapping Around (ALKS) Price Events - Stock Traders Daily
Alkermes Jumps 6.9% After Needham Maintains Buy - AlphaStreet
ALKS Maintained by Needham -- Price Target Raised to $61.00 - GuruFocus
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tel - GuruFocus
ALKS Maintained by TD Cowen -- Price Target Raised to $50 - GuruFocus
Alkermes plc (ALKS) Stock Analysis: Navigating Growth in Biopharmaceuticals with a 4.88% Upside - DirectorsTalk Interviews
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes announces orphan drug designations for Alixorexton in the US and Europe - MSN
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.63%
1.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):